[go: up one dir, main page]

WO2002069691A3 - Immunogenic hiv peptides for use as reagents and vaccines - Google Patents

Immunogenic hiv peptides for use as reagents and vaccines Download PDF

Info

Publication number
WO2002069691A3
WO2002069691A3 PCT/US2002/006314 US0206314W WO02069691A3 WO 2002069691 A3 WO2002069691 A3 WO 2002069691A3 US 0206314 W US0206314 W US 0206314W WO 02069691 A3 WO02069691 A3 WO 02069691A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
vaccines
reagents
hiv peptides
immunoreactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/006314
Other languages
French (fr)
Other versions
WO2002069691A2 (en
Inventor
Janet M Mcnicholl
Kyle Bond
Busarawan Sriwanthana
Chou-Pong Pau
Anne Degroot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University Research Foundation Inc
Centers of Disease Control and Prevention CDC
US Department of Health and Human Services
Original Assignee
Brown University Research Foundation Inc
Centers of Disease Control and Prevention CDC
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Research Foundation Inc, Centers of Disease Control and Prevention CDC, US Department of Health and Human Services filed Critical Brown University Research Foundation Inc
Priority to EP02721225A priority Critical patent/EP1490396A4/en
Priority to JP2002568886A priority patent/JP2004535369A/en
Priority to CA002439990A priority patent/CA2439990A1/en
Publication of WO2002069691A2 publication Critical patent/WO2002069691A2/en
Anticipated expiration legal-status Critical
Publication of WO2002069691A3 publication Critical patent/WO2002069691A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Immunogenic HIV peptides and methods of use are provided in which each HIV peptide include epitopes that are immunoreactive with cytotoxic T lymphocytes (CTLs) from HIV-positive individuals and binds to antibodies that are immunoreactive with the assembled class I major histocompatibility complex (MHC) structure. Preferably, the peptide is an isolated or synthetic peptide containing between nine and eleven amino acid residues within specific regions of the HIV genome.
PCT/US2002/006314 2001-03-01 2002-03-01 Immunogenic hiv peptides for use as reagents and vaccines Ceased WO2002069691A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02721225A EP1490396A4 (en) 2001-03-01 2002-03-01 IMMUNOGENEOUS HIV PEPTIDES FOR USE AS REAGENTS AND VACCINES
JP2002568886A JP2004535369A (en) 2001-03-01 2002-03-01 Immunogenic HIV peptides for use as reagents and vaccines
CA002439990A CA2439990A1 (en) 2001-03-01 2002-03-01 Immunogenic hiv peptides for use as reagents and vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27256501P 2001-03-01 2001-03-01
US60/272,565 2001-03-01

Publications (2)

Publication Number Publication Date
WO2002069691A2 WO2002069691A2 (en) 2002-09-12
WO2002069691A3 true WO2002069691A3 (en) 2004-09-16

Family

ID=23040344

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006314 Ceased WO2002069691A2 (en) 2001-03-01 2002-03-01 Immunogenic hiv peptides for use as reagents and vaccines

Country Status (4)

Country Link
EP (1) EP1490396A4 (en)
JP (1) JP2004535369A (en)
CA (1) CA2439990A1 (en)
WO (1) WO2002069691A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635876A (en) 2000-02-04 2005-07-06 杜克大学 Human immunodeficiency virus vaccine
BRPI0514447B8 (en) * 2004-08-17 2021-05-25 Centre Nat Rech Scient use of the immunosuppressive function of a human or simian immunodeficiency virus accessory protein for the preparation of a vaccine
EP1797175B1 (en) * 2004-10-04 2008-07-16 Biovaxim Limited Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
KR20080106467A (en) 2006-03-10 2008-12-05 펩트셀 리미티드 Peptides, Compositions and Methods of Using HIV Modulators or Supplementary Proteins
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AIDS, vol. 14, no. 11, 2000, pages F111 - F115 *
CHUNG H.C. ET AL.: "Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti- peptideMHC monoclonal antibody", JOURNAL OF IMMUNOLOGY, vol. 167, 2001, pages 699 - 707, XP002903695 *
DATABASE PROTEIN [online] XP002903693, accession no. NCBI Database accession no. (AAG36866) *
DE BERARDINIS P. ET AL.: "Phage display of peptide epitopes from HIV - 1 elicits strong cytotoxic responses", NATURE BIOTECHNOLOGY, vol. 18, August 2000 (2000-08-01), pages 873 - 876, XP002161760 *
FOUNG S.K. ET AL.: "A monoclonal antibody against HLA - A11 and A24", HUMAN IMMUNOLOGY, vol. 15, no. 3, March 1986 (1986-03-01), pages 316 - 9, XP002903694 *
KIRKSEY T.J. ET AL.: "The structural basis for the increased immunogenicity of two HIV reverse transcriptase peptide variant/class I major histocompatibility complexes", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 52, 1999, pages 37259 - 37264, XP002903696 *
ZHANG Q.J. ET AL.: "Solvent exposed side chains of peptides bound to HLA A*1101 have similar effects on the reactivity of alloantibodies and specific TCR", INTERNATIONAL IMMUNOLOGY, vol. 8, no. 6, June 1996 (1996-06-01), pages 927 - 38, XP008040475 *

Also Published As

Publication number Publication date
JP2004535369A (en) 2004-11-25
EP1490396A2 (en) 2004-12-29
EP1490396A4 (en) 2006-04-19
CA2439990A1 (en) 2002-09-12
WO2002069691A2 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
BR9812139A (en) Vaccine
JP2003528887A5 (en)
WO1999033868A3 (en) Human papillomavirus vaccine
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
DK1278534T3 (en) Methods and compositions for attenuating the multiplication of HIV-1
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2363947A1 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
UA85536C2 (en) Viral antigens
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
EP1461079B8 (en) Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
WO2010022740A3 (en) Hiv-1 envelope polypeptides for hiv vaccine
CA2389206A1 (en) Activation of hcv-specific t cells
WO2002068654A3 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
Sattentau et al. Antibody neutralization of HIV-1 and the potential for vaccine design
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
WO2002002738A3 (en) Host cells containing multiple integrating vectors
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
CA2554195A1 (en) Peptide originating in epidermal growth factor receptor (egfr)
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
AU2003241127A1 (en) MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
Bartnes et al. A retro‐inverso analog mimicks the cognate peptide epitope of a CD4+ T cell clone
WO2004041842A3 (en) Epitopes of hepatitis c virus
WO2003029285A3 (en) Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
CA2431881A1 (en) Polypeptide inducing hiv-neutralising antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002252166

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002568886

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2439990

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002721225

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002721225

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002721225

Country of ref document: EP